Zhitong Finance App News, Genting Xinyao (01952.HK) issued an announcement. China's National Drug Administration (NMPA) has approved the new drug marketing license application for Starbital® (etripamil nasal spray) to treat acute episodes of paroxysmal supraventricular tachycardia (PSVT) in adults, which reverted to sinus rhythm.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.